ArticlePathogens (Basel, Switzerland)2025
Changing Epidemiology of
Article in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diversity of Candida spp. isolated from microbiota and infectious processes in wild mammals: a systematic review.Veterinary research communications · 2026Pooled it
- Contemporary Trends in Candidemia: Mortality, Species, and Antifungal Resistance Across Three Periods (2017-2025) in Houston, Texas.Open forum infectious diseases · 2026Article
- Emergence and Comparative Analysis ofJournal of fungi (Basel, Switzerland) · 2026Article
- Pediatric candidemia epidemiology and antifungal susceptibility profiles reported by the ISPED program in China, 2016-2024.Antimicrobial agents and chemotherapy · 2026Article
- Microbial profile and antimicrobial resistance patterns in clinical specimens from a secondary-level hospital in Accra, Ghana: a five-year retrospective study.BMC microbiology · 2026Article
- Candidemia Epidemiology and Antifungal Resistance in Critically-ill Patients During and After COVID-19 Pandemic: Comparison Between Two Hospitals in Greece and Türkiye.Mycopathologia · 2026Article
- Invasive Candidiasis in Critically Ill Patients: Fundamental Concepts and Future Directions.Chest · 2026Review
- Article
- Clinical Determinants of 30-Day Mortality in Candidemia: Antifungal Susceptibility and Treatment Patterns in a 10-Year Cohort.Antibiotics (Basel, Switzerland) · 2026Article
- Mortality ofJournal of fungi (Basel, Switzerland) · 2026Article
- Trends in candidemia and antifungal resistance: a nine-year single-center study in Turkey.BMC infectious diseases · 2026Article
- Evaluation of an Antifungal Agent Against Nakaseomyces Glabratus in the in Vivo Model Galleria Mellonella.Current microbiology · 2026Article
- Clinical Characteristics, Antifungal Therapy, and Outcomes ofInfection and drug resistance · 2026Article
- Antifungal Stewardship in the Pediatric Intensive Care Unit: Time is of the Essence.Infection and drug resistance · 2026Review
- Outbreak of mucocutaneousAntimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Antifungal Activities of Multi-Halogenated Indoles Against Drug-ResistantInternational journal of molecular sciences · 2025Article
- Article
- Epidemiology and outcomes of Candida-associated osteoarticular infections: A multicentre retrospective study from Turkey.Medical mycology · 2025Article
- A Comprehensive Review of Antibiotic Resistance in the Oral Microbiota: Mechanisms, Drivers, and Emerging Therapeutic Strategies.Antibiotics (Basel, Switzerland) · 2025Review
- Chimeric Antigen Receptor Immunotherapy for Infectious Diseases: Current Advances and Future Perspectives.Pathogens (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe epidemiology of candidemia has shifted in the past few decades; drug-resistant
methodsAll unique
resultsCandidemia incidence increased during the COVID-19 pandemic, from 0.63/1000 patient-days in 2020 to 0.96/1000 patient-days in 2022, and has since slightly decreased (0.83 and 0.89 in 2023 and 2024, respectively). Candidemia-associated mortality was high (>50%) in 2020 and peaked during the pandemic. During the study period,
conclusionsA high prevalence of azole resistance of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.